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RESEARCH ARTICLE

Efﬁcient killing of tumor cells by CAR-T cells requires greater
number of engaged CARs than TCRs
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Although CAR-T cells are widely used to treat cancer, efﬁciency of CAR-T cell cytolytic responses has not been carefully
examined. We engineered CAR speciﬁc for HMW-MAA (highmolecular-weight melanoma-associated antigen) and evaluated
potency of CD8+ CAR-T cells to release cytolytic granules and
to kill tissue-derived melanoma cells, which express different
levels of HMW-MAA. CAR-T cells efﬁciently killed melanoma
cells expressing high level of HMW-MAA, but not melanoma
cells with lower levels of HMW-MAA. The same melanoma
cells presenting signiﬁcantly lower level of stimulatory peptideMHC ligand were readily lysed by T cells transduced with
genes encoding α,β-TCR speciﬁc for the peptide-MHC ligand.
The data suggest that higher level of targeted molecules is
required to engage a larger number of CARs than TCRs to
induce efﬁcient cytolytic granule release and destruction of
melanoma cells. Understanding the difference in molecular
mechanisms controlling activation thresholds of CAR- versus
TCR-mediated responses will contribute to improving efﬁciency of CAR T cells required to eliminate solid tumors presenting low levels of targeted molecules.

Strategies that enhance the immune response to eliminate
tumor cells have evolved into the rapidly growing ﬁeld of
immunotherapy, which has offered promising results in
treating several types of cancer (1–4). While chemotherapy
and radiation treatments can cause extensive off-target
toxicity, properly designed immunotherapeutic interventions
to combat cancer appears to be more speciﬁc and minimize
damage to healthy host tissues. Engineered T cells directed
against tumor cells offer an innovative immunotherapy that is
rapidly becoming widely used (5).
Transduction of T cells with chimeric antigen receptors
(CARs) recognizing selected cell surface molecules
demonstrated successful application of this technology for
treatment of hematologic malignancies (2). However, targeting tumors in tissues by CAR-T cells has proved to be
challenging with signiﬁcantly lower success rate and the
development of adverse effects (e.g., (6)). A limited access of
CAR-T cells to tumors inside tissues, tumor
* For correspondence: Yuri Sykulev, Yuri.Sykulev@Jefferson.edu.

microenvironment, and cross-reactivity of CAR-T cells with
antigens in healthy tissues are well-identiﬁed problems
(7–9). However, the role of the level of targeting antigen on
solid tumors and the level of CAR expression that both
determine efﬁciency of CAR-mediated response have not
been carefully evaluated.
CARs comprise an engineered fusion receptor containing
an extracellular single chain variable fragment (scFv), a hinge
or stalk region that is typically derived from CD8, a transmembrane domain, and intracellular signaling domains (8,
10). The scFv is engineered from variable domains of heavy
and light chains of an antibody with the speciﬁcity of interest. This “chimeric moiety” will bind speciﬁcally to a
desired targeting molecule on tumor cells. The hinge region
of CAR is designed to allow spatial arrangement and ﬂexibility for the scFv allowing CAR molecules to form dimers at
the cell surface. This permits antigen binding at otherwise
unfavorable distances and angles between targeting molecules. The transmembrane and intracellular signaling domains of CAR often contain intracellular portions of CD28
and CD3ζ or other domains of signaling and costimulatory
molecules in T cells.
We engineered CD8+ CAR-T cells recognizing highmolecular-weight melanoma-associated antigen (HMWMAA) that is overexpressed on the surface of up to 90% of
melanoma cells (11). Also, known as chondroitin sulfate proteoglycan 4 (CSPG4), HMW-MAA plays a pivotal role in cell
migration and metastasis (11). The level of HMW-MAA
expression is varied on different melanoma cell lines. We
compared potency of the speciﬁc lysis of these melanoma cells
that express different levels of HMW-MAA by CD8+ CAR-T
cells. For comparison reasons, we also tested efﬁcacy of the
same target cell destruction by T cells transduced with genes
encoding α,β-TCR speciﬁc for cognate peptide-MHC (pMHC)
ligands presented on the target cells at a signiﬁcantly lower
level. The results led us to conclude that TCR triggering of
cytolytic response has a lower threshold as opposed to that
required to initiate response by CAR even though both receptors were expressed on T cells at a very similar level. This
suggests that higher numbers of engaged CARs than TCRs are
required to achieve similar potency of cytolytic response by
CAR-T and TCR-T cells.
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CAR versus TCR triggering of T-cell cytolytic response
Results
Strategy of the proposed analysis
To compare efﬁciency of the cytolytic effector functions of
CD8+ CAR-T with that of human virus-speciﬁc CD8+ CTL, we
chose widely used design of CAR (Fig. 1A) speciﬁc for HMWMAA, which is usually overexpressed on melanoma cells. To
produce CAR-T cells, we utilized cord-blood-derived T cells
that contain mostly naïve T cells compared with more diverse
T cells from adult individuals. Cord blood T cells possess a
high proliferative capacity, allowing to readily expand these
cells to produce sufﬁcient amount of CAR-T cells required for
analysis (Fig. 1B). Activated cord-blood-derived T cells were
transduced with a retroviral pBMN-I vector coexpressing GFP
and the C21CD28CD3ζ CAR. The killing efﬁciency of puriﬁed
CD8+ CAR-T cells was compared with CER43 and 68A62
CTLs as well as with that of CD8+ T cells transduced with
genes encoding α and β chains of D3 TCR (D3TCR-T cells) by
testing ability of these cytolytic effectors to kill melanoma cell
lines that display various levels of either HMW-MAA protein
or cognate peptides bound to MHC class I proteins. The
magnitude and sensitivity of the cytolytic activity of the
effector cells and the extent of their degranulation have been
compared.

Generation of HMW-MAA-speciﬁc CAR-T cells and D3TCR-T
cells recognizing SL9 peptide in association with HLA-A2
We transduced activated T cells derived from cord blood
with a HMW-MAA-speciﬁc CAR. The transduction yielded
5% GFP+ cells. High-expressing GFP cells were sorted out
using ﬂow cytometry. Additional round of stimulation was
performed as needed to expand the transduced cells and

CD8+ CAR-T cells were isolated by negative immunomagnetic sorting. The purity of isolated CD8+ CAR-T cells
was conﬁrmed by ﬂow cytometry (Fig. 2A). The CAR-T cells
were stained with ﬂuorescent-labeled penta-His antibody to
estimate the level of expression of His-tagged CAR. Using
calibrating ﬂuorescent beads, we determined an average of
12,700 CAR receptors per CD8+ T cell (Fig. S1A). To produce D3TCR-T cells speciﬁc for HIV Gag-derived SLYNTVATL (SL9) peptide in association with HLA-A2, α and
β D3TCR genes were transduced into activated freshly isolated T cells using similar vector containing BFP allowing to
select high-expressing BFP T cells by ﬂow cytometry sorting.
After additional stimulation and expansion of transduced T
cells, CD8+ T cells were selected by negative immunomagnetic sorting, and purity of CD8+ T cells was characterized by ﬂow cytometry (Fig. 2B). The level of D3TCR
expression was measured by staining of CD8+ T cells with
ﬂuorescent labeled anti-Vβ5.1 antibody and subsequent
comparison of the ﬂuorescence intensity with calibrating
ﬂuorescent beads as described for CAR-T cells. An average
of 11,900 D3TCR was expressed per CD8+ T cell.
The level of expression of targeting HMW-MAA on melanoma
tumor cells is widely varied
We utilized ﬂuorescent labeled HMW-MAA-speciﬁc antibodies and calibrating ﬂuorescent beads to evaluate the level of
HMW-MAA expression on different melanoma cell lines. We
found that skin melanoma cells express higher surface levels of
HMW-MAA as compared with uveal melanoma cells (see
Table 1 and Fig. S2). Skin A375 melanoma cells were estimated
to present 280,000 HMW-MAA molecules per cell. The
patient-derived skin melanoma cell line CM006 was found to

Figure 1. Production and testing of CD8+ CAR-T cells speciﬁc for high-molecular-weight melanoma-associated antigen. A, the structure of CAR; the
CAR was inserted into retroviral vector containing GFP. B, transduction of cord blood derived T cells with CAR caring retrovirus and comparison CD8+ CAR-T
cell and CTL functional activities.
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Figure 2. Level of CAR and D3TCR expression transduced into CD8+ T
cells. A, CAR expression on CAR-transduced (right) or control (left) CD8+ T
cells. PBMCs were transduced with GFP-labeled pBMN-I retrovirus containing CAR or with a mock vector and GFP positive cells were sorted by Flow
Cytometry. CD8+ T cells were isolated from stimulated GFP-positive T cells
by magnetic sorting. Expression of CAR on CD8+GFP+ T cells was conﬁrmed
by staining with anti-His-tag Alexa Fluor 647 antibody (see Fig. S1).
Representative GFP and Alexa Fluor 647 dot-plot is shown (N = 3). CAR
expression level was equal 12,700 ± 2900 receptors per cell (mean ± SD) as
determined from three independent experiments. B, D3TCR expression on
CD8+ T cells transduced with pMSCV-IRES-Blue FP vector or with mock
vector. BFP positive cells were sorted by ﬂow cytometry, and CD8+ T cells
were puriﬁed by magnetic sorting. The TCR expression was determined
from comparison of ﬂuorescence intensity of Vβ5.1 antibody bound to TCR
on CD8+BFP+ cells with ﬂuorescence intensity of calibrating ﬂuorescent
beads. The level of D3TCR expression was determined to be 11,900 ± 900
receptors per cell.

express 120,000 HMW-MAA molecules per cell. In contrast,
patient-derived uveal melanoma cell lines UM004 and
UM002B displayed 52,000 and 4000 molecules per cell,
respectively.
Target antigen expression level strongly inﬂuences CARmediated cytolytic activity and release of cytolytic granules
We ﬁrst tested efﬁciency of CD8+ CAR-T cells to kill skin
and uveal melanoma tumor cells expressing different levels of
HMW-MAA. CD8+ CAR-T cells efﬁciently lysed the highexpressing A375 cells (280,000 HMW-MAA molecules/
cell) and CM006 cells (120,000 HMW-MAA molecules/cell)
Table 1
Expression of HMW-MAA on a surface of melanoma cells

a

Melanoma cell line

Melanoma type

HMW/MAA/cella

A375
CM006
UM004
UM002B

Skin
Skin
Uveal
Uveal

280,000
119,000
52,000
4000

Mean ± SD calculated from three independent experiments.

±
±
±
±

50,000
31,000
24,000
1700

even at low effector-to-target ratios (E:T = 5:1) (Fig. 3). CD8+
CAR-T cells lysed speciﬁcally the low-expressing cell line
UM004 (52,000 HMW-MAA molecules/cell) but the killing
was marginal. The killing of UM002B (4000 HMW-MAA
molecules/cell) was still detectable at high E:T ratios.
To reiterate the observed difference in speciﬁc lysis of
melanoma cells by CD8+ CAR-T cells, we analyzed the release
of cytolytic granules by the effector cells in response to
recognition of the same melanoma cells. To this end, the
effector cells were cocultured with the melanoma cells at
various density of the target cells, and the degranulation
marked by surface expression of CD107a was evaluated. The
recognition of A375 target cells that display the highest
number of HMW-MAA per cell led to detectable expression of
CD107a marker on the surface of CD8+ CAR-T cells (Fig. 4A).
The appearance of CD107a on the same effector cells in
response to recognition of CM006, UM004, or UM002B was
below detectable level (Fig. S3).
In addition to measuring the appearance of CD107a on the
surface of the effector cells during coculturing with tumor
cells, we also evaluated serine esterase activity of granzymes, a
component of cytolytic granules, released to the culture supernatant. The amount of the released granzymes was
measured from changes in adsorption spectrum of converted
by the granzyme substrate added to the extracellular medium
(see Experimental procedures for details). CD8+ CAR-T cells
released detectable amount of granules followed by recognition of A375 target cells (Fig. 4B). The amount of released
granules by CD8+ CAR-T cells in response to recognition of
CM006, UM004, and UM002B target cells was undetectable
(Fig. S3).
Collectively, CD8+ CAR-T cells only released measurable
amounts of granules in response to tumor cells expressing high
levels of targeting antigen HMW-MAA on the cell surface.
However, the amount of released granules was signiﬁcantly
diminished compared with previously observed for both CD4+
and CD8+ CTL stimulated via TCR (12).
CTLs effectively lyse melanoma cells and release cytolytic
granules even when presented with a low level of cognate
pMHC ligands
To determine whether melanoma tumor cells possess any
intrinsic resistance to cytolytic response exercised by CD8+
CAR-T cells, we exploited the human Flu-speciﬁc cloned CTL
CER43 to examine killing of the same HLA-A2 melanoma cells
sensitized with various concentrations of cognate Flu-derived
peptide GL9 to generate GL9-HLA-A2 ligands on the cell
surface recognizable by CER43 CD8+ CTL. Indeed, the CTL
speciﬁcally lysed each of the melanoma cell lines even when
the lines were sensitized at very low peptide concentration
resulting in signiﬁcantly lower level of GL9-HLA-A2 ligands
on the surface of target cells as compared with HMW-MAA
antigens (Fig. 5A and Table 2). Similar data were produced
with HIV-speciﬁc CTL clone 68A62 that recognizes
ILKEPVHGV (IV9) peptide in the context of HLA-A2
(Fig. S4).
J. Biol. Chem. (2021) 297(3) 101033
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Figure 3. Destruction of melanoma cells that express various levels of HMW-MAA by CD8+ CAR-T cells. Cytolytic activity by CD8+ CAR-T cells against
melanoma cell line A375 (A), CM006 (B), UM004 (C), and UM002B (D) is shown. Estimated numbers of HMW-MAA molecules per each melanoma cell surface
are indicated. CD8+ T cells transduced with “empty” vector were utilized as control effector cells. All assays were performed in triplicates. Means and SD are
calculated for each point, and the error bars are indicated for each mean value. p-values were calculated by Student’s t test, and p-values for statistically
signiﬁcant results are indicated for each point (****p < 0.0001; ***p < 0.001; **p < 0.01; *p < 0.05). Data shown are representative of 3 to 5 independent
experiments.

We also tested the extent of CER43 CTL degranulation in
response to TCR engagement by cognate GL9-HLA-A2 ligand
on the surface of the melanoma cell lines. CER43 CTLs were
cocultured with target cells presenting varying levels of
cognate pMHC ligands and percent of degranulating CTL was
determined by measuring upregulation of CD107a on the cell
surface. In parallel, serine esterase release was also quantiﬁed.
The fraction of CD107a expressing CTL and percent of
released granules in response to the CTL stimulation with the
melanoma cell lines were signiﬁcantly higher than those
observed for CD8+ CAR-T cells targeting the same melanoma
cells even at signiﬁcantly lower level of stimulatory pMHC
ligands on target cells (Figs. 4 and 5, B and C).
The observed killing of the melanoma cells by CER43 CTL
and 68A62 CTL as well as by CD8+ CAR-T cells was
completely inhibited in the presence of EGTA (Fig. S5) indicating that the killing induced by all tested effector cells was
granule-mediated.
These data suggest that failure of CD8+ CAR-T cells to exert
cytolytic activity against melanoma is attributed to inability of
CARs to induce sufﬁcient release of cytolytic granules. This is

Figure 4. Degranulation efﬁciency of CD8+ CAR-T cells induced by A375
melanoma cell line. A, percent of responding effector cells against
A375 cells was determined by measuring appearance of CD107a on the
surface of responding cells. B, the extent of cytolytic granule release by
effector cells in response to recognition of A375 cells was quantiﬁed by
measuring serine esterase activity in extracellular medium. The results are
representative of at least three independent experiments. Each experimental value represents the mean of triplicate. Standard deviations are
indicated for each point as error bars. p-values were calculated by Student’s
t test (*p < 0.05; **p < 0.01; ***p < 0.001).
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despite high level of expression of targeted molecule on melanoma cells recognizable by CARs with a high afﬁnity
(2 × 107 L/M) (13) as opposed to lower afﬁnity of TCR for
cognate pMHC (2 × 105 L/M) (14). However, CAR expression
of engineered T cells is substantially lower (≈12,700 CARs per
cell) than TCR expression on CTL (30,000–60,000 TCR per
cell depending on a day after stimulation) (Anikeeva and
Sykulev, unpublished results).

D3TCR-T cells effectively lyse melanoma cells
To directly compare efﬁciency of CAR-mediated and TCRmediated killing of target cells, we engineered D3TCR-T cells,
which expressed ≈12,000 D3TCR per cells, very similar to
average number of CAR per T cell (Fig. 2). We also determined
the number of cognate pMHC on A375 and UM004 cells. To
this end, we counted the number of ﬂuorescent labeled peptide
AF647-IV9 bound to accessible cell surface HLA-A2 molecules on the melanoma cells by comparing the ﬂuorescence
intensity with that of calibrated ﬂuorescent beads (see
Experimental procedures for details) (Fig. S6). We previously
exploited this peptide (15) and showed that labeled and unlabeled peptides bound equally well to cell surface HLA-A2.
The binding afﬁnity of ILKEPVHGL (IV9) peptide to HLAA2 has been determined (KD = 2 × 10−7 M) (16) and was
similar to estimated afﬁnities of SL9 and GL9 peptides for
HLA-A2 (Fig. S7). We found that at the peptide concentration
10−7 M in the extracellular medium, 1100 and 1400 peptide
molecules per cell are presented by HLA-A2 on A375 and
UM004 melanoma cells, respectively. At this peptide concentration, killing capacity of A375 and UM004 by 68A62 CTLs at
E:T = 5:1 approaches its maximum (Fig. S4).
We evaluated speciﬁc lysis of melanoma cells by engineered
D3TCR-T cells and compared with the ability of CAR-T cells
to kill the same target cells. 51Cr-labeled A375 and
UM004 cells were combined with D3TCR-T cells at various
E:T ratios in the presence of SL9 peptide added to the extracellular media at 10−7 M concentration; the peptide was kept
in the media during the assay. Figure 6 shows that D3TCR-T
cells efﬁciently lysed both A375 and UM004 cells. Even
though lysis of A375 cells by CAR-T cells (see Fig. 3A) was

CAR versus TCR triggering of T-cell cytolytic response

Figure 5. CER43 CD8 T cell clone cytolytic response and degranulation efﬁciency induced by melanoma cell lines presenting cognate pMHC ligands at various levels. Cytolytic activity (A), appearance of CD107a (B), and serine protease release (C) were measured for each indicated target cell line
sensitized with cognate peptide. Peptide concentration required for 50% of maximal lysis (SD50) of each target cell line is indicated by an arrow. Each
experimental point was tested in triplicates in at least three independent experiments. Representative experiments are shown, and mean values with
standard deviation are indicated for each experimental point. p-values that are statistically different from corresponding value obtained with target cells not
pulsed with peptide are indicated (*p < 0.05; **p < 0.01; ***p < 0.001, two-tailed Student’s t test).

comparable to that induced by D3TCR-T cells, the level of
HMW-MAA molecules per target cells was 200 times higher
than the level of cognate pMHC on these cells recognizable by
D3TCR-T cells. UM004 melanoma cells that display 52,000
HMW-MAA molecules per cell were killed very poorly by
CAR T cells (see Fig. 3C) as opposed to more efﬁcient killing of
these cells by D3TCR-T cells that responded to 1400 cognate
pMHC ligands per target cell. It has to be noted that average
level of CAR and D3TCR receptors on engineered T cells was
very similar, 12,700 and 11,900 receptors per cells,
respectively, but intrinsic afﬁnity of these receptors for cognate
ligands is 2 × 107 L/M and 2.4 × 105 L/M, correspondingly
(13, 14). These data suggest that more CARs need to be

engaged as compared with D3TCRs to initiate comparable Tcell cytolytic response. Thus, TCR appears to be more superior
to CAR in triggering cytolytic response by CD8+ T cells.

Discussion
The major ﬁnding from described experiments is that
comparison of the potency of two different receptors to trigger
cytolytic activity revealed superiority of TCR over CAR. Our
data clearly demonstrated that efﬁcient killing of melanoma
cells can be achieved only at high level of HMW-MAA antigen
expression on melanoma cells. In contrast, CTL and TCR-T
cells efﬁciently destroy melanoma presenting signiﬁcantly

Table 2
Number of GL9-HLA-A2 complexes per melanoma cell at antigenic peptide concentration required for half maximal cell lysis (SD50) by CER-43
CTL
Melanoma cell line
A375
CM006
UM004
UM002B

Melanoma type
Skin
Skin
Uveal
Uveal

Total HLA-A2/cella
77,400
68,700
82,500
3000

±
±
±
±

5860
9480
8664
1400

GL9 concentration at SD50b, M
−10

1 × 10
2 × 10−8
2 × 10−9
3 × 10−9

GL9-HLA-A2/cell at SD50c
<48
<7579
<1010
<93

Mean ± SD calculated from three independent experiments; There are statistically signiﬁcant difference in HLA-A2 expression level between UM002B cells and A375 (p < 0.01),
CM006 (p < 0.01), and UM004 (p < 0.001) cell lines as determined by one-way ANOVA followed by Tukey post hoc test. There was no statistically signiﬁcant difference between
A375, CM006, and UM004 lines.
b
Determined from cytolytic assay with CER-43 CTL and GL9-sensitized melanoma cells.
c
Number of pMHC ligands per cell calculated in the assumption that all cell surface MHCs are receptive for peptide loading. The occupancy of the “empty” HLA-A2 molecules is
calculated using the equation: α = KeqC/(1 + KeqC), where α is fraction of HLA-A2 molecules on a cell surface occupied by GL9 peptide, K equilibrium binding constant for
interaction between peptide and MHC (Keq = 6.2 × 106 L/M) (48); C is peptide concentration at SD50. Actual number of GL9-HLA-A2 per cell is lower than those indicated
because the calculation performed in the assumption that all HLA-A2 molecules on the cell surface are receptive for peptide loading.
a
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Figure 6. Speciﬁc lysis of A375 and UM004 melanoma cells by D3TCR-T
cells. The level of expression of targeted SL9-HLA-A2 ligands per cell
recognizable by D3TCR-T cells as well as E:T ratios are indicated. Percent of
speciﬁc lysis of the target cells sensitized with 10−7 M of SLYNYVATL (SL)
peptide is indicated by closed circles. Extent of the target cell lysis sensitized
with irrelevant peptide GILGFVFTL (GL9) is shown by open circles. p-values
were calculated by Student’s t test, and p-values for statistically signiﬁcant
results are indicated for each point (****p < 0.0001; ***p < 0.001; **p <
0.01; *p < 0.05). Data shown are representative of three independent
experiments.

lower level of cognate pMHC ligands. Further support for the
difference between the two cytolytic effectors attacking tumor
cells is provided by striking disparity in the appearance of
CD107a on CTL and CAR-T cells indicative of membrane
fusion events of specialized lysosomes containing perforin and
granzyme with the cell membrane on the effector cells. In total,
60 to 70% of CTL attacking melanoma cells upregulate CD107a
as opposed to only 20% of responding CAR-T cells that are
capable to do so (see Figs. 4A and 5B). Consistent with this,
CTLs could release up to 50% of all available cytolytic granules,
while CAR-T cells excreted only 20% at maximum (Figs. 4B
and 5C). Efﬁcient killing of melanoma cells was also observed
by primary CD8+ CTL derived from melanoma lesions (17).
To provide additional evidence, we evaluated potency of
killing by engineered T cells transduced with TCR that was
expressed on T cells at the same level as CAR was. The afﬁnity
of TCR was signiﬁcantly lower than that of CAR for the
cognate ligands recognizable by the two receptors. At the same
time, the level of HMW-MAA ligands on melanoma cells
targeted by CAR-T cells was considerably higher as opposed to
the level of pMHC ligands recognized by TCR-T cells.
Nevertheless, TCR-T cells demonstrated more efﬁcient
response than CAR-T cells against the same melanoma cells
(Figs. 3 and 6). These data clearly point to inefﬁcient use of the
available cellular machinery for granule delivery by T cells in
response to CAR triggering. Molecular basis of this disparity
remains to be elucidated.
Because the level of antigen expression on target cells inﬂuences the magnitude and sensitivity of T cell responses (18,
19), it is expected that tumor-speciﬁc response of engineered
cytolytic effectors would also depend on the level of targeting
molecules on tumor cells. Indeed, tumor cells strategically
downregulate MHC proteins or mutate tumor-associated antigens (TAA) to evade destruction by immune cells (20–24).
Although level of targeting molecules presented on tumor
cells is clearly essential, the origin of transformed cells appears

6 J. Biol. Chem. (2021) 297(3) 101033

to be an important factor that also determines the sensitivity to
cytolytic granule-mediated attack. Lymphoblasmoid cell lines
are generally known to be “conventional targets” to study
T-cell cytolytic responses because these cells are more sensitive to granule-mediated lysis than tissue-derived tumor cells
(25). Not surprisingly, initial success of targeting lymphoblastic
malignancies by CAR-T cells (26) led to a dramatic increase in
the popularity of CAR T cells engineering. In another example,
erythroleukemia cells K562 transduced with CD19 that is
expressed at relatively lower level could still be efﬁciently killed
by CD19-speciﬁc CAR-T cells (27). It has been shown that
erythrocyte membrane is very sensitive to cytolytic granules
(28) explaining that K562 cells could be readily destroyed even
at a relatively low level of targeting molecules expression.
Thus, the nature of tumor cells appears to be another
important factor determining the susceptibility of their killing.
One way to improve the sensitivity of responsiveness of
engineered T cells is to endow T cells with high-afﬁnity TCR
(29). However, antigen recognition by high-afﬁnity TCRs does
not always induce an optimal T-cell response and often mediates off-target toxicity or apoptosis of the T cells (30, 31).
This led to a notion that T cells having a moderate TCR afﬁnity could be more effective. In fact, we have previously
shown that afﬁnity of TCR on T cells approaches a “ceiling”
(18), which is sufﬁcient to initiate T-cell response even to a few
stimulatory peptide-MHC ligands on target cells (32), and
further increase in TCR afﬁnity does not improve the sensitivity of the response.
While our data show that efﬁcient cytolytic response of
CD8+ CAR-T cells is limited by expression level of targeted
molecules on melanoma cells (Table 1 and Fig. 3), much fewer
activating pMHC ligands on the same target cells are needed
to initiate cytolysis by the CTLs (Table 2 and Fig. S2) and
TCR-T cells (Fig. 6). This suggests that signiﬁcantly more
CARs than TCRs are required to be engaged to initiate sufﬁcient cytolytic activity by CD8+ CAR-T cells. Consistent with
this, variations of the expression level of TCR controlled by
inducible promotor in TCR transgenic mice revealed that even
as low as 1/20th the normal TCR numbers on the T cells was
still sufﬁcient to initiate T-cell response with no indication of
phenotypic skewing (33). Most likely, signal ampliﬁcation
induced by TCR is much more potent than that triggered by
CAR. This is in accord with previously ﬁndings showing that
T cells transduced with αβ TCR genes demonstrated more
superior cytolytic activity compared with the T cells endowed
with CAR containing variable domains of the same TCR (34).
In addition, it has been recently shown that CAR mediates very
inefﬁcient recruitment of ZAP70 that leads to signiﬁcantly
lower sensitivity of CAR-T cell responses to target cells (35).
We have previously found that the kinetics of degranulation,
which is regulated by the kinetics of Ca2+ signaling, is the
major factor controlling the efﬁciency of cytolytic activity
(36, 37). The kinetics of accumulation and sustained level of
intracellular calcium controls functioning of dynein motors
that moves cytolytic granules along microtubules toward the
MTOC (36, 38). The MTOC polarization and its close juxtaposition to the target cell-contacting membrane are a second
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important factor that controls efﬁciency of cytolytic granule
delivery by CTL (38, 39). CAR engagement does not lead to
complete MTOC polarization and results in initial rapid
intracellular Ca2+ accumulation, which then abruptly declined
(40). Thus, the difference in the kinetics of calcium mobilization induced by CAR or TCR implies that CAR-mediated
release of cytolytic granules is transient as opposed to TCRinduced degranulation. Indeed, T cells stimulated through
CAR demonstrated inefﬁcient granules release (see Fig. 4B).
Swift and sustained TCR signaling can mediate rapid granule
release and efﬁcient killing of target cells at lower effector-totarget ratio and scarce density of epitopes on the target cell
(41). Transient calcium signaling could also cause rapid
detachment of CD8+ CAR-T cells from target cells (40) that is
counterproductive to efﬁcient attack by effector cells.
Consistent with this, LFA-1 plays an essential role in killing of
target cells by CTL (42), while the role of LFA-1 in cytolytic
activity by CAR-T cells is not entirely clear.
We conclude that CD8+ CAR-T cells are less sensitive than
CTL and TCR-T cells in the detection and killing of tumor
cells. Thus, higher level of targeted molecules on tumor cells
resulting in a greater number of engaged CARs than TCRs is
required for successful attack of tumor cells. Understanding
mechanisms responsible for this disparity is warranted as it
will provide basis to advance engineering of CAR-T cells that
could be exploited to ﬁght solid tumors that present low levels
of targeted molecules.

Experimental procedures
Melanoma cell lines and packaging cell line
Uveal and skin melanoma cell lines were cultured in RPMI
1640 medium supplemented with 10% FBS, 1% L-Glutamine,
1% Penicillin, 1% HEPES, and 1% non-essential amino acids
(complete RPMI medium). Human skin melanoma cell line
CM006 and uveal melanoma cell lines UM004 and UM002B
were established and characterized in Dr Takami Sato laboratory. The A375 human malignant skin melanoma cell line
was supplied by ATCC and was maintained in DMEM containing 10% FBS, 1% L-Glutamine, and 1% Penicillin. The
Phoenix amphotropic packaging cell line was purchased from
ATCC and was cultured in DMEM supplemented with 10%
FBS, 1% L-Glutamine, and 1% Penicillin. The cells were utilized for generation of retrovirus for transduction.
Cytotoxic lymphocytes
The CD8+ CTL clone CER43 for Flu-derived peptide
GILGFVFTL was kindly provided by Dr Antonio Lanzavecchia
and the HIV-speciﬁc CD8+ CTL clone 68A62 that recognizes the
reverse transcriptase-derived peptide ILKEPVHGV (IV9) was a
gift from Dr Bruce Walker. Both clones were stimulated and
maintained in culture as previously described (12, 36, 42, 43).
Antibodies and calibrating beads
Hybridoma OKT3 producing mouse antibodies speciﬁc for
human CD3ε was purchased from ATCC. Hybridoma PA2.1
expressing antibody speciﬁc for the α2 helix of HLA-A2 was a

gift of Herman Eisen, Massachusetts Institute of Technology.
OKT-3 and PA2.1 antibodies were puriﬁed from hybridoma
cultural supernatant using afﬁnity chromatography with protein A. Puriﬁed PA2.1 antibody was labeled with Alexa Fluor
488 in correspondence with manufacturer instruction (Molecular Probes, Thermo Fisher Scientiﬁc). Stimulatory antibody against CD28 (clone 9.3) was purchased from GeneTex.
Antibody speciﬁc for CD107a PE (clone H4A3) was obtained
from BD Pharmingen. Anti-His tag antibody was purchased
from Qiagen. Anti-TCR Vβ5.1 antibody was supplied by Miltenyi Biotec. The following antibodies were used for quantiﬁcation assays: anti-6-Histidine Tag Alexa Fluor 647 (clone
AD1.1.10; Novus Biological), anti-HMW-MAA (NG2) Alexa
Fluor 488 (clone 9.2.27, eBioscience), anti-TCR Vβ5.1 (clone
REA1062, Miltenyi Biotec). Alexa Fluor 488, R-PE, and antiAlexa Fluor 647 calibrating beads from Bangs Labs Quantum
MESF kits were exploited to measure the number of HMWMAA, CAR, and TCR molecules on target and effector cells,
respectively.
Puriﬁcation and stimulation of human T cells
Human peripheral blood mononucleated cells (PBMCs)
were puriﬁed by Ficoll-Hypaque density centrifugation from
decoded cord blood samples provided by the Department of
Gynecology at Thomas Jefferson University. Ficoll-Hypaque
(GE Healthcare) was added to a mixture of blood and DPBS
at 1:2 ratio and centrifuged for 30 min @ 2200 rpm with no
brake, at 18  C. The PBMC layer was extracted and washed
three times with RPMI medium. The PBMC mixture was
incubated in 10 cm Petri dish for 1 h at 37  C to remove
adherent cells, and nonadherent cells were collected. T25 ﬂask
was precoated with 10 μg/ml anti-CD3 and 1 μg/ml anti-CD28
antibodies in DPBS buffer. The subsequent PBMC population
was incubated in the ﬂask in the presence of 100 U/ml of
human IL2 to activate T cells.
Generation of HMW-MAA speciﬁc CAR and HIV
Gag p1777–85-speciﬁc D3 TCR constructs, production of
retrovirus, and transduction of effector cells
To produce the CAR construct, we utilized human single
chain antibody scFvC21 against HMW-MAA antigen, which
were isolated from a semisynthetic phage display scFv antibody
library (13, 44). His6 tag was introduced at N-terminal end.
Gene encoding VL and VH single-chain fragment was fused
with genes encoding CD8 alpha hinge region, CD28 transmembrane and signaling domains, and CD3ζ signaling domain
and cloned into the pBMN-I-GFP retroviral vector (a gift from
Dr Garry Nolan). To generate D3 TCR retroviral construct, D3
TCR-alpha and D3 TCR-beta genes (14) were fused using 2A
sequence and cloned into pMSCV-IRES-Blue FP vector.
pMSCV-IRES-Blue FP was a gift from Dario Vignali (Addgene
plasmid # 52115). To generate retrovirus, Phoenix-Ampho
cells were transfected with the recombinant plasmid using
Lipofectamine LTX with Plus reagent (Life Technology). Supernatants containing the retrovirus were collected 48 and
72 h later. Activated human T cells (mixture of CD4+ and
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CD8+ T cells) were combined with recombinant virus and
Lipofectamine LTX with Plus reagent. The mixture was
centrifuged at 700g for 90 min, and the cells were incubated
overnight at 37  C in IL-2 containing complete media. Next
day the same procedure was repeated with freshly collected
virus supernatant. Transduction efﬁciency was measured by
ﬂow cytometry using GFP or BFP as a marker. The cells were
grown for at least 6 days before sorting.
Puriﬁcation of CD8+ CAR- and D3TCR-T cells
GFP+ T cells were sorted using a BD Fortessa Flow Cytometer to isolate CAR-expressing T cells. The resultant heterogeneous CD4+ and CD8+GFP+ T cell population expressing
high levels of GFP was expanded and then was subjected to
negative immunomagnetic sorting (Miltenyi Biotech) to purify
CD8+ CAR-T cells. Cell surface expression of CAR was veriﬁed
with biotinylated antibody against His6 Tag (Novus Biologicals). CD8+BFR+D3TCR-T cells were isolated in a similar
manner. Cell surface expression of D3 TCR was veriﬁed by
staining with R-PE labeled antibody against TCR Vβ5.1 (Miltenyi Biotec).
Quantiﬁcation of cell surface receptors
Fluorescent labeled beads from Bangs Labs Quantum MESF
kits were used to estimate the number of HMW-MAA and
HLA-A2 on target cells as well as CAR and D3 TCR molecules
on transduced T cells. Corresponding ﬂuorescent beads were
placed into individual 5 ml polystyrene ﬂow cytometry tubes
containing 400 μl of FACS buffer (DPBS +2% FBS). Fluorescent
labeled antibodies speciﬁc for HMW-MAA or HLA-A2 were
used to stain target cells. Anti-His tag antibody was utilized to
stain CAR on the T cell surface. Fluorescent intensity associated with the stained cells was measured by ﬂow cytometry and
related to the ﬂuorescent intensity of the calibrating beads
according to the instructions provided by Bangs Labs.
The number of IV9-HLA-A2 complexes on A375 and
UM004 cells was directly measured using IV9 variant
ILKEPVHCV that was stoichiometrically labeled with Alexa
Fluor 647 at the penultimate Cysteine (15). The peptide labeling at the Cysteine does not impair the peptide binding to
HLA-A2 (45). A375 and UM004 melanoma cells were pulsed
with various concentrations of ILKEPVHC(Alexa Fluor 647)V
(IV9-AF647) peptide for 1 h at 37  C in the presence or
absence of 100-fold excess of unlabeled IV9 peptide. The cells
were washed free of unbound peptide and associated with the
cell ﬂuorescence was measured by ﬂow cytometry. The
numbers of the peptides bound to the cell surface HLA-A2
were determined using calibrating Alexa Fluor 647 beads.
The number of IV9-HLA-A2 complexes on the cell surface
was calculated as the difference between total numbers of
bound IV9-AF647 peptides and numbers of the labeled peptides bound to the cell surface in the presence of 100-fold
excess of cold peptide.
The number of stimulatory GILGFVFTL-HLA-A2 complexes on the same target cells was measured at the peptide
concentration required to induce half maximal lysis (SD50)
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(19, 46, 47). The number of pMHC ligands per cell were
calculated using law of mass action: α = KeqC/(1 + KeqC),
where α is fraction of HLA-A2 molecules on a cell surface
occupied by GL9 peptide, K equilibrium binding constant for
interaction between peptide and MHC (Keq = 6.2 × 106 for
HLA-A2 and GL9 interaction (48)); C is peptide concentration
at SD50. SLYNTVATL (SL9) peptide from HIV-1 p17
Gag(77–85) (46) was synthesized by the Protein/peptide Core
facility of Massachusetts General Hospital. Custom synthesis,
puriﬁcation (more than 95%), and characterization of
ILKEPVHC(Alexa647)V peptide were performed by ProImmune Ltd. The peptide GILGFVFTL (GL9) from matrix protein of Flu virus (49) was synthesized by Research Genetics, Inc
and the peptide purity (>96%) was conﬁrmed by HPLC and
mass spectrometric analysis. ILKEPVHGV (IV9) peptide from
HIV reverse transcriptase (46) was a gift from Herman Eisen.
Chromium release assay
Speciﬁc lysis of the target cells by cytotoxic lymphocytes was
tested as previously described (19, 32). 1 × 106 melanoma
target cells were labeled with 200 μCi of 51Cr (PerkinElmer) for
1 h, washed free of unreacted chromium, and were plated at
5 × 103 cells/well in a round-bottomed 96-well plates. Engineered cytolytic effectors were then added to the plates at
various effector-to-target ratio, and the plates were incubated
for 4 h at 37  C in a CO2 incubator. To block granzyme/
perforin-mediated pathway of target cell killing, cytolytic
assay was performed in the presence of 2 mM EGTA.
Cytolytic potency of the human CTLs (CER43 and 68A62)
was examined against the same HLA-A2+ melanoma target
cells sensitized with GL9 or IV9 cognate peptides. Various
amounts of the peptide in 50 μl of Dulbecco’s PBS were
combined with 100 μl of 51Cr-labeled target cells and 2.5 × 104
CTL in 50 μl of complete medium in round-bottomed 96-well
plates at an effector-to-target cell ratio of 5:1. The plates were
incubated for 4 h at 37  C in a CO2 incubator.
To measure cytolytic response of D3TCR-T cells, 1 × 106
A375 or UM004 melanoma target cells were labeled with Cr51
as above and combined with D3TCR-T cells in 96-well plates
at various E:T ratios in the presence of either cognate (SL9) or
noncognate (GL) peptides added to the extracellular media at
10−7 M.
51
Cr release in the supernatant was quantiﬁed by automatic
Gamma Counter (PerkinElmer). Percent speciﬁc lysis was
calculated from the average of triplicates as follows: 100 ×
([51Cr experimentally released − spontaneous release]/
[maximum release in 0.1% NP40 − spontaneous release]).
CD107a granule release assay
Degranulation of CAR-T cells and CTLs was measured by
appearance of CD107a on the surface of responding cytolytic
effectors, as previously described (50). Effector cells in complete RPMI 1640 media containing PE-labeled anti-CD107a
antibodies were combined with target cells at various densities
in ﬂat bottom 96-well plates. The plates were incubated for 4 h
at 37  C in CO2 incubator. Effector cells were then harvested
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and analyzed for appearance CD107a on the surface by ﬂow
cytometry using PE-labeled anti-human CD107a antibodies
(BD Pharmingen). The percent of responding effector cells was
determined.

Serine esterase release assay
The extent of degranulation of the effector cells
responding to the target cells was evaluated by measuring
serine-esterase activity of granzymes, a component of
released cytolytic granules as previous described with some
modiﬁcation (12). The cytolytic effectors were combined
with live target cells at various densities as above. Following
incubation, plates were spun down for 5 min at 1300 rpm. In
total, 100 μl of supernatant was removed from each well and
placed into a fresh 96-well ﬂat bottom plate; 50 μl of 2 mM
5,50 -dithio-bis-[2-nitrobenzoic acid] (DTNB or Ellman’s
Reagent) in assay buffer (0.15 M NaCl, 0.01 M Hepes) was
added to each well. The plate was incubated at room temperature for 15 min, and then 50 μl of 0.8 mM
benzyloxycarbonyl-L-lysine thiobenzyl ester (BLT), a substrate for serine esterases, was added in assay buffer to each
well followed by incubation for 30 min at 37  C. The substrate digestion resulted in the color change of absorbed light
measured at 405 nm by automatic ELISA plate reader. An
equal number of effector cells were also lysed using two
liquid nitrogen freeze–thaw cycles to determine maximal
release of serine esterases. Percent released granules was
calculated from the average of triplicates as follows: 100 ×
([experimental granule release − spontaneous release]/[total
release after LN2-mediated lysis − spontaneous release]).

Data availability
All data presented in the manuscript could be shared upon
request.
Supporting information—This
information.
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